Cencora, Inc.

COR 10-Q · Q2 2026
API behind this page

COR Q2 2026 request

Playground key active
Request URL /api/financials?ticker=COR&year=2026&quarter=2
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q2 2026 Q2 2025 YoY
Revenue 78,355,916 75,453,673 +3.8%
Show Product Lines breakouts
Alliance Healthcare · International Healthcare Solutions 6,516,466 5,771,991 +12.9%
Animal Health · Corporate Non Segment 1,435,789 1,363,032 +5.3%
Other Healthcare Solutions · International Healthcare Solutions 1,049,283 924,788 +13.5%
Other non-strategic businesses · Corporate Non Segment 619,782 593,375 +4.5%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 7,565,749 6,696,779 +13.0%
U. S. Healthcare Solutions · Operating Segments 68,765,078 66,819,265 +2.9%
Show Consolidation Items breakouts
Corporate Non Segment 2,055,571 1,956,407 +5.1%
Intersegment Elimination -30,482 -18,778 -62.3%
Cost of Revenue 74,767,577 72,393,864 +3.3%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 6,751,460 5,980,518 +12.9%
U. S. Healthcare Solutions · Operating Segments 66,512,805 64,937,891 +2.4%
Show Consolidation Items breakouts
Corporate Non Segment 1,743,941 1,638,025 +6.5%
Intersegment Elimination -26,214 -17,872 -46.7%
Operating Segments 74,981,992 72,538,562 +3.4%
Gross Profit 3,588,339 3,059,809 +17.3%
Selling, General & Administrative 1,977,559 1,600,040 +23.6%
Depreciation Nonproduction 132,136 121,815 +8.5%
Amortization Of Intangible Assets 117,156 138,003 -15.1%
Litigation Settlement Expense 13,858 11,524 +20.3%
Show Consolidation Items breakouts
Material Reconciling Items 13,858 11,524 +20.3%
Business Combination Acquisition Related Costs 164,164 99,380 +65.2%
Show Consolidation Items breakouts
Material Reconciling Items 164,164 99,380 +65.2%
Restructuring Charges 40,873 52,857 -22.7%
Show Consolidation Items breakouts
Material Reconciling Items 40,873 52,857 -22.7%
Operating Income 1,142,593 1,036,190 +10.3%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 175,797 154,598 +13.7%
U. S. Healthcare Solutions · Operating Segments 998,300 944,969 +5.6%
Show Consolidation Items breakouts
Corporate Non Segment 91,633 92,851 -1.3%
Intersegment Elimination -2,381 -154 -1446.1%
Operating Segments 1,263,349 1,192,264 +6.0%
Non-Operating Income (Expense) -1,086,439 3,546 -30738.4%
Interest Income Expense Nonoperating Net 140,460 103,988 +35.1%
Income Before Taxes 2,088,572 928,656 +124.9%
Income Tax Expense (Benefit) 459,044 211,239 +117.3%
Net Income 1,629,528 717,417 +127.1%
Show Equity Components breakouts
Noncontrolling Interest -11,804 -454 -2500.0%
Retained Earnings 1,641,332 717,871 +128.6%
Net Income Loss Attributable To Noncontrolling Interest 11,804 454 +2500.0%
Net Income 1,641,332 717,871 +128.6%
EPS (Basic) 8.44 3.7 +128.1%
EPS (Diluted) 8.4 3.68 +128.3%
Wtd Avg Shares (Basic) 194,545 193,796 +0.4%
Wtd Avg Shares (Diluted) 195,383 195,094 +0.1%
Common Stock Dividends Per Share Declared 0.6 0.55 +9.1%
Operating Expenses 2,110,575 1,722,847 +22.5%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 638,492 561,663 +13.7%
U. S. Healthcare Solutions · Operating Segments 1,253,973 936,405 +33.9%
Show Consolidation Items breakouts
Corporate Non Segment 219,997 225,531 -2.5%
Intersegment Elimination -1,887 -752 -150.9%
Comprehensive Income 1,585,102 915,657 +73.1%

Balance Sheet

Balance Sheet
Metric Q2 2026 Q2 2025 YoY
Current Assets
Cash & Cash Equivalents 2,176,496 1,978,061 +10.0%
Accounts Receivable 24,893,220 23,715,008 +5.0%
Inventory 20,010,006 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 284,941 — —
Contract With Customer Asset Gross Current 1,574,708 1,301,531 +21.0%
Prepaid Expenses & Other Current Assets 636,815 574,871 +10.8%
Assets Of Disposal Group Including Discontinued Operation Current 3,849,666 — —
Show Disposal Group Classification breakouts
Disposal Group Heldforsale Not Discontinued Operations 3,849,666 — —
Total Current Assets 53,140,911 46,534,973 +14.2%
Non-Current Assets
Property, Plant & Equipment 2,805,419 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 77,182 — —
Goodwill 16,452,669 — —
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 2,613,296 — —
U. S. Healthcare Solutions · Operating Segments 13,839,373 — —
Deferred Tax Assets 192,825 233,700 -17.5%
Other Non-Current Assets 3,005,560 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 108,359 — —
Total Assets 81,652,100 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 895,898 — —
Intangible Assets (Q) — — —
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,683,551 3,392,058 -20.9%
Other Intangible Assets 3,354,165 — —
Other Assets
Intangible Assets Net Excluding Goodwill 6,054,716 3,862,835 +56.7%
Current Liabilities
Accounts Payable 51,881,816 50,110,563 +3.5%
Accrued Liabilities 3,195,861 2,447,498 +30.6%
Debt Current 202,660 770,321 -73.7%
Liabilities Of Disposal Group Including Discontinued Operation Current 851,949 — —
Show Disposal Group Classification breakouts
Disposal Group Heldforsale Not Discontinued Operations 851,949 — —
Total Current Liabilities 56,132,286 53,328,382 +5.3%
Current Portion of Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
Alliance Healthcare debt 48,643 7,125 +582.7%
Multi-currency revolving credit facility due in 2030 28,744 708,000 -95.9%
Nonrecourse debt 77,772 55,196 +40.9%
OneOncology physician notes 47,501 — —
Non-Current Liabilities
Long-Term Debt 12,182,860 7,085,886 +71.9%
Accrued Income Taxes Noncurrent 352,768 277,738 +27.0%
Deferred Tax Liabilities 1,748,178 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 7,977 — —
Litigation Reserve Noncurrent 3,856,483 4,284,602 -10.0%
Show Litigation Case breakouts
Opioid Lawsuits and Investigations 3.9 4.3 -9.3%
Other Non-Current Liabilities 3,794,575 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 82,910 — —
Long-Term Debt 12,385,520 — —
Show Debt Instrument breakouts
$1,000,000, 2.700% senior notes due 2031 994,398 — —
$1,000,000, 4.900% senior notes due 2036 989,677 — —
$500,000, 2.800% senior notes due 2030 497,480 — —
$500,000, 3.950% senior notes due 2029 496,984 — —
$500,000, 4.250% senior notes due 2030 496,108 — —
$500,000, 4.250% senior notes due 2045 495,901 — —
$500,000, 4.300% senior notes due 2047 494,221 — —
$500,000, 4.600% senior notes due 2033 496,502 — —
$500,000, 4.625% senior notes due 2027 497,921 — —
$500,000, 5.125% senior notes due 2034 495,398 — —
$500,000, 5.650% senior notes due 2056 491,643 — —
$600,000, 4.850% senior notes due 2029 597,006 — —
$700,000, 5.150% senior notes due 2035 695,186 — —
$750,000, 3.450% senior notes due 2027 748,570 — —
Alliance Healthcare debt 48,643 — —
Multi-currency revolving credit facility due in 2030 28,744 — —
Nonrecourse debt 200,341 — —
OneOncology physician notes 380,404 — —
Term loan due in 2027 799,300 — —
Term loan due in 2028 299,630 — —
Term loan due in 2029 999,076 — —
€500,000, 2.875% senior notes due 2028 572,378 — —
€500,000, 3.625% senior notes due 2032 570,009 — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 122,569 — —
Total Liabilities (Q) — — —
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 681,895 — —
Other Liabilities
Minority Interest 187,360 166,962 +12.2%
Stockholders' Equity
Common Stock 2,983 2,972 +0.4%
Additional Paid In Capital Common Stock 6,301,973 6,142,056 +2.6%
Retained Earnings 8,491,234 6,401,534 +32.6%
Accumulated Other Comprehensive Income -961,308 -1,201,838 +20.0%
Treasury Stock Common Value -10,437,292 -10,331,887 -1.0%
Total Stockholders' Equity 3,397,590 1,012,837 +235.5%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 3,584,950 1,179,799 +203.9%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -961,308 -1,201,838 +20.0%
Additional Paid In Capital 6,301,973 6,142,056 +2.6%
Common Stock 2,983 2,972 +0.4%
Noncontrolling Interest 187,360 166,962 +12.2%
Retained Earnings 8,491,234 6,401,534 +32.6%
Treasury Stock Common -10,437,292 -10,331,887 -1.0%
Total Liabilities & Equity 81,652,100 71,193,874 +14.7%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q2 2026 YTD Q2 2025 YoY
Operating Activities
Depreciation 277,549 237,226 +17.0%
Adjustment For Amortization 249,699 308,219 -19.0%
Provision For Doubtful Accounts -4,872 12,355 -139.4%
Deferred Income Taxes 192,769 21,133 +812.2%
Stock-Based Compensation 94,056 98,836 -4.8%
Inventory L I F O Reserve Period Charge -287,592 32,145 -994.7%
Show Consolidation Items breakouts
Material Reconciling Items -287,592 32,145 -994.7%
Inflationary Accounting Impact 19,197 26,060 -26.3%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 97,582 37,460 +160.5%
Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss -1,086,612 — —
Equity Investment Remeasurement Gain Loss -10,501 -3,300 -218.2%
Gain Loss On Sale Of Other Assets -36,050 — —
Other Non-Cash Items 1,045 9,814 -89.4%
Change in Accounts Receivable -308,675 -218,043 -41.6%
Change in Inventory -120,202 34,252 -450.9%
Change in Prepaid & Other Assets 54,104 94,273 -42.6%
Change in Accounts Payable -2,193,885 -669,479 -227.7%
Increase Decrease In Accrued Liabilities -257,394 -489,470 +47.4%
Increase Decrease In Income Taxes Payable And Other Liabilities -91,900 -145,700 +36.9%
Net Cash from Operations -966,530 632,456 -252.8%
Depreciation & Amortization 509,693 538,310 -5.3%
Show Business Segments breakouts
International Healthcare Solutions · Operating Segments 72,744 64,459 +12.9%
U. S. Healthcare Solutions · Operating Segments 166,246 133,061 +24.9%
Show Consolidation Items breakouts
Corporate Non Segment 29,269 38,923 -24.8%
Investing Activities
Capital Expenditures -284,994 -234,953 -21.3%
Payments To Acquire Businesses Net Of Cash Acquired -4,932,036 -3,947,761 -24.9%
Proceeds From Sale Of Other Productive Assets 43,774 — —
Payments To Acquire Equity Method Investments -19,210 -192,576 +90.0%
Payments For Proceeds From Notes Receivable 20,626 -34,814 +159.2%
Other Investing Activities -2,376 -10,558 +77.5%
Net Cash from Investing -5,174,216 -4,420,662 -17.0%
Financing Activities
Proceeds From Issuance Of Debt 4,648,203 3,320,674 +40.0%
Repayments Of Long Term Debt -349,493 -548,565 +36.3%
Proceeds From Lines Of Credit 71,004,546 43,631,727 +62.7%
Repayments Of Lines Of Credit -70,925,495 -42,948,335 -65.1%
Payments Of Dividends Common Stock -243,972 -222,076 -9.9%
Tax Withholding for Share Compensation -105,186 -77,558 -35.6%
Proceeds From Payments For Other Financing Activities -6,832 -2,984 -129.0%
Net Cash from Financing 4,021,771 2,717,412 +48.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations -14,825 -48,520 +69.4%
Cash Cash Equivalent Restricted Cash And Restricted Cash Equivalent Period Increase Decrease Including Exchange Rate Effect Disposal Group Held For Sale Not Discontinued Operations -2,133,800 -1,119,314 -90.6%
Disposal Group Including Discontinued Operation Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -24,487 — —
Net Change in Cash -2,158,287 -1,119,314 -92.8%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2,236,262 2,178,566 +2.6%
Show Consolidated Entities breakouts
Variable Interest Entity Primary Beneficiary 10,366 — —

Values in thousands USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key